ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

China's New Regulation on Internet Healthcare Will Benefit Platforms like WeDoctor

HONG KONG, Oct 29, 2021 - (ACN Newswire) - On 27 October, China's National Health Commission (NHC), the authority responsible for the medical industry, issued a new policy that calls for the regulation of China's fast-growing internet healthcare industry. The policy is expected to push China's internet healthcare industry from the period of minimal regulatory constraints into the era of standardized development.

According to the NHC, as of June 2021, the number of internet hospitals in China has exceeded 1,600, the internet hospital is the provider of online medical services such as online consultations. The first Internet hospital in China was established in 2015 in Wuzhen, Zhejiang province by digital medical service platform WeDoctor.

This policy has generated widespread interest within the Chinese healthcare industry since its release, and the regulatory measures taken by Beijing on the education and training industry since the third quarter of this year have caused participants in various industries to be very concerned about the potential impact of the regulation. Unlike the education and training industry, the regulatory policy on online medical consultation has been well received within the industry, with the release of the policy seen as beneficial to the development of the internet healthcare industry, especially for some of large digital medical platforms that engage strictly online medical services.

The document, titled "Rules on the Regulation of Online Medical Consultation (Draft for Comments)", states that physicians are required to authenticate their real identity before providing consultations to ensure that such online consultations are provided by the said doctor. Other people, AI software, etc. are not allowed to impersonate or replace the physicians themselves. As a result, some companies that focusing on using AI technology to provide consultation services may be negatively impacted.

China does not allow internet healthcare platforms to use consultations as a tool for the sale of prescription drugs. The policy proposes that the occurrence of unified prescriptions and prescription refills is prohibited, that the personal income of healthcare workers must not be linked to income from drugs and medical examinations, and that doctors must not designate locations to purchase drugs and consumables.

In a report published by the People's Daily, Liao Jieyuan, founder of China's largest digital medical service platform WeDoctor, believes that the policy has released a clear signal that online medical consultation should be of the same quality as that provided by physical institutions, reflecting China's determination to develop digital medical services, which is essential for the standardized development and market expansion of the Internet healthcare industry.

The healthcare services and physical hospitals nowadays in China are unable to meet the huge demand of its 1.4 billion population. Platforms such as WeDoctor have leveraged technology to help alleviate the demand and supply imbalance in China's healthcare industry.

According to a publicly released research report by CICC, with the regulatory policies for internet healthcare becoming more transparent and standardized, companies providing actual medical services with a sound regulatory compliance system are expected to benefit the most.

(Source: Bloomberg Terminal)





Copyright 2021 ACN Newswire . All rights reserved.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.